We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Radiotherapy Provides Relief for Patients with Painful Heel Spurs

By HospiMedica International staff writers
Posted on 08 Aug 2012
Patients with plantar fasciitis experience substantially less pain and improved quality of life following a standard dose of external beam radiation therapy, a commonplace cancer treatment similar to receiving an X-ray, according to a randomized, cooperative group study.

The study’s findings were published online July 31, 2012, in the International Journal of Radiation Oncology-Biology-Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO). More...
Approximately 8%-10% of the population has severe bone heel spurs, with the most common treatments for alleviating the pain being ice, heat, and various anti-inflammatory medications. Steroids and local anesthetics can be injected, and oral analgesic medications may be ordered, but most of these techniques have only provided short-term pain relief. The results of this study demonstrated that up to 80% of standard dose patients experienced complete pain relief, and pain relief remained constant or even improved for up to 64% of the study participants during the follow-up period of 48 weeks post-treatment.

“Severe plantar fasciitis is a chronic health issue, and it can be extremely painful--many of these men and women cannot walk or stand for a long time,” said Marcus Niewald, MD, PhD, a radiation oncologist at Saarland University Medical Center (Homburg/Saar, Germany), and one of the study’s authors. “Radiation therapy has been used for its anti-inflammatory effect for more than 60 years. We are extremely encouraged by the results of our research because evidence of improved quality of life for patients is clearly evident with the standard dose regimen.”

This study was a prospective, randomized trial of a total of 66 patients, with assessment every six weeks until 12-months post treatment. Four patients were secondarily excluded after the trial began; 29 patients received a standard dose regimen, and the remaining 33 patients received a low dose of radiation therapy. The standard dose patients were treated with a total dose of 6.0 Gy, applied in six single fractions of 1.0 Gy twice weekly on nonconsecutive days. The low dose arm received 0.6 Gy, applied in six single fractions of 0.1 Gy twice weekly on nonconsecutive days.

Related Links:

Saarland University Medical Center




Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.